With cold and flu season around the corner, Doctors recommend receiving the RSV vaccine ahead of the holidays.

Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Then in October, the FDA expanded the approval of Pfizer's bivalent RSV prefusion F vaccine (Abrysvo) to include adults ages ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

In times of market uncertainties, high-dividend yield stocks are ideal investment choices for their qualities like stable passive income, protection against inflation, and price appreciation. Thus, ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...